Apellis Pharma Flunks On Primary, Secondary Endpoints In Amyotrophic Lateral Sclerosis Study
Portfolio Pulse from Vandana Singh
Apellis Pharmaceuticals' Phase 2 MERIDIAN study for amyotrophic lateral sclerosis (ALS) failed to meet its primary and key secondary endpoints. As a result, Apellis and Swedish Orphan Biovitrum plan to discontinue the development of systemic pegcetacoplan for ALS.
May 25, 2023 | 5:14 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Apellis Pharmaceuticals' stock price may be negatively impacted by the failure of its Phase 2 MERIDIAN study for ALS and the discontinuation of systemic pegcetacoplan development.
The failure of the Phase 2 MERIDIAN study and the discontinuation of systemic pegcetacoplan development for ALS are significant setbacks for Apellis Pharmaceuticals. Investors may react negatively to this news, leading to a decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Swedish Orphan Biovitrum's stock price may be negatively impacted by the discontinuation of systemic pegcetacoplan development for ALS, as it was a partner in the project.
Swedish Orphan Biovitrum was a partner in the development of systemic pegcetacoplan for ALS. The discontinuation of the project may negatively impact the company's stock price, as it represents a setback in their product pipeline.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 80